Diabetes Mellitus Clinical Trial
— DoDoPiOfficial title:
Comparing Door-to-door Versus Community Gathering in Providing HIV Counseling and Testing Within an Integrated Primary Health Care Package: a Cluster Randomized Trial in Rural Lesotho
Verified date | February 2012 |
Source | SolidarMed |
Contact | n/a |
Is FDA regulated | No |
Health authority | Lesotho: Ministry of Health and Social Welfare |
Study type | Interventional |
The purpose of this trial is to determine if door-to-door is more effective than community gathering in providing voluntary HIV counseling and testing (VCT) in communities in rural Lesotho. The voluntary HIV counseling and testing will be proposed as an integrated part of a package of proposed services. The package consists of: Blood-pressure measurement, blood-glucose measurement, Body-mass-index (adults), weight for height (children), catch-up vaccinations, deworming (children) Vitamin A (children & young women), family planning for eligible women, Tuberculosis screening and HIV counseling and testing.
Status | Completed |
Enrollment | 1800 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion criteria: - Not already known to be HIV-positive - Resident in the catchment area of the health center where the campaign is conducted - Provision of written informed consent to participate (signed by writing or fingerprint) - In case of children: Provision of written informed consent by an adult care-taker |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
Lesotho | Seboche Hospital | Seboche | Botha-Bothe |
Lesotho | Paray Hospital | Thaba-Tseka |
Lead Sponsor | Collaborator |
---|---|
SolidarMed | Paray Mission Hospital, Thaba-Tseka, Seboche Hospital, Botha-Bothe |
Lesotho,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of newly tested HIV-positive clients over all clients tested for HIV during the campaigns | Proportion refers to the proportion of newly tested HIV-positive clients among all clients tested for HIV during the voluntary counselling and testing campaigns in each arm. | No | |
Primary | Proportion of clients newly tested HIV-positive who enrolled into HIV/AIDS care within one month over all clients newly tested HIV-positive during the campaigns | One month after the campaigns, enrollment of clients who newly tested HIV-positive at the campaign is assessed at the facilities based on the clinics' registers. | 4 weeks after tested positive | No |
Primary | Overall number newly tested HIV-positive and enrolled into chronic HIV/AIDS-care at each facility | Between the two study-arms, the overall numbers will be compared in two ways: Total number positively tested and enrolled into care at the facility during the month after the campaign (this refers to the overall number at facility-level. Irrespective if these patients were tested during one of the campaigns or during routine activities at the facility) Total number positively tested and enrolled into care from the 5 villages where campaigns were held as compared to the five villages where no campaigns were held. |
4 weeks after campaign | No |
Primary | Absolute number of newly tested HIV-positive clients | Refers to the overall number newly tested HIV-positive during the campaigns in both arms | No | |
Primary | Absolute number of clients newly tested HIV-positive who enrolled into HIV/AIDS care | This refers to the absolute number newly tested HIV-positive during the campaigns who enrolled thereafter into chronic HIV/AIDS care within one month | 4 weeks after tested HIV-positive | No |
Secondary | CD4-count among clients newly tested HIV-positive | CD4-counts will be measured on site using a Point-of-care machine. | No | |
Secondary | Clinical WHO-stage among clients newly tested HIV-positive | No | ||
Secondary | Proportion of clients screened positive for Tuberculosis during the campaigns | All clients accessing services (irrespective of HIV-status) will be screened for TB by a nurse. Clients with a positive screening are provided sputum bottles and are entered in the Tuberculosis-suspect register. | No | |
Secondary | Proportion of first-time HIV-testers among all clients accessing the testing services | No | ||
Secondary | Proportion of clients with positive tuberculosis screening who return 3 sputum-bottles within = 5 days to the facility | Tuberculosis-suspect registers and tuberculosis registers at the facility are used for verification | 5 days after the campaign was held | No |
Secondary | Proportion of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear. | Tuberculosis suspect registers and Tuberculosis registers at the facility are used for verification. | 5 days after the campaign was held | No |
Secondary | Demographic characteristics of clients accessing the voluntary counseling and testing services | No | ||
Secondary | Absolute number of clients accessing the services at the campaigns who have a positive screening for Tuberculosis | No | ||
Secondary | Absolute number of clients with positive tuberculosis screening who return 3 sputum-bottles within = 5 days to the facility | = 5 days after the campaigns | No | |
Secondary | Absolute number of clients with a positive Tuberculosis-screening who return their sputum-bottles and who have at least one AFB-positive smear. | = 5 days after the campaign | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |